Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BEE'en PLUS is a topical combination cream developed and marketed by Community Pharmacy PCL (Chumchon) in Thailand. It contains a combination of the corticosteroid triamcinolone acetonide, the aminoglycoside antibiotic neomycin sulfate, and the antifungal agent nystatin. The product is indicated for the treatment of inflammatory skin conditions (dermatoses) that are complicated by, or at risk of, secondary bacterial or candidal infections. Triamcinolone acetonide provides anti-inflammatory and antipruritic effects by activating glucocorticoid receptors. Neomycin sulfate exerts antibacterial activity by binding to the bacterial 30S ribosomal subunit and inhibiting protein synthesis. Nystatin provides antifungal activity by binding to ergosterol in the fungal cell membrane, leading to membrane leakage and cell death.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BEE'en PLUS.